Array BioPharma, Inc.
) recently announced a strategic worldwide research &
development collaboration. The agreement is for a preclinical
program (discovered by Array BioPharma) aimed at a novel
As per the terms of the agreement, Array BioPharma will receive
an $11 million upfront payment from Celgene while the latter will
have the option to license several clinical development
candidates. Moreover Array BioPharma is eligible to receive up to
$376 million on the achievement of specified development,
regulatory and sales milestones.
The company is also eligible for royalties on sales of any
drugs developed and commercialized under this deal. Array
BioPharma will reserve all the rights under the program if
Celgene does not exercise the granted option.
ACTELION LTD (ALIOF): Get Free Report
ARRAY BIOPHARMA (ARRY): Free Stock Analysis
CELGENE CORP (CELG): Free Stock Analysis
ONCOTHYREON INC (ONTY): Free Stock Analysis
To read this article on Zacks.com click here.
Array BioPharma has been quite active in collaboration activities
this year. Earlier this month, the company entered into a
multi-year licensing and collaboration deal with Loxo Oncology
for a preclinical development candidate (discovered by Array
BioPharma) and related intellectual property.
Furthermore, in May 2013, Array BioPharma entered into a
collaboration agreement with
) to develop and commercialize ARRY-380, which is being developed
for the treatment of breast cancer.
We note that Array BioPharma has entered into several
collaborations with big companies and amassed a total of $577.9
million in research funding and upfront and milestone payments
from collaboration partners from inception till Jun 30, 2012.
The company is focused mainly on the development and
commercialization of targeted small molecule drugs for the
treatment of cancer patients. We also note that the company has a
few candidates approaching phase III by the end of 2013.
Currently, Array BioPharma carries a Zacks Rank #2 (Buy).
However, biopharma stocks such as
) look more attractive with a Zacks Rank #1 (Strong Buy).